EU nod for new formulation of Biogen’s Tysabri
A subcutaneous formulation will now be available to treat relapsing-remitting multiple sclerosis
Read More
Tag: sub-cutaneous
Sub-cutaneous form of Entyvio hits PhIII safety, efficacy goals
Takeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
